NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
A video you MUST SEE–an ex-Zyprexa sales rep spills the beans!
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
The lead story in The New York Times on Thanksgiving day (below) acknowledged several facts demonstrating that children are the victims of major medical malpractice:
Dr. E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University, acknowledges: “The system of diagnosis is still 200 to 300 years behind other branches of medicine.” Psychiatry also fails to be guided by an evidence-based positive benefit / risk assessment of its prescribed treatments.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
How to earn promotions in pharmaceutical industry Tue, 6 Sep 2005 In the world of pharmaceuticals, careers are made by marketing the worst products that cause the greatest harm. Contact: Vera Hassner Sharav 212-595-8974 XenoPort Appoints Gary D. Tollefson, Former Lilly Executive, to Board Company Snapshot: XNPThttp://www.xenoport.com SANTA CLARA, Calif.,…
Two-thirds foster care children in Mass on psych drugs_Globe Psychiatry: Soviet Experience–American Fallacy Wed, 11 Aug 2004 The Boston Globe reports that 2/3 of children in state care in Massachusetts are being “treated” for mental illness with psychotropic drugs. Marie Parente, a legislator, and parents call for disclosure of “how…
Psychiatry and Preschoolers Tue, 1 Jul 2003 There was a time that doctors followed the precautionary “do no harm” principle when prescribing drugs. But the practice of medicine has changed radically as physicians have increasingly become financially tied to the pharmaceutical industry. Among psychiatrists it is difficult to find one…
Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs – WSJ Fri, 29 Jul 2005 The Wall Street Journal uncritically reported: “The results of the largest studies ever conducted of depression and schizophrenia will be released in coming months, potentially transforming the way patients are treated and shaking…
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
A Lobbying Campaign for Screening Children for Mental Problems–a Gimmick Aimed at Increasing PhRMA Profits Wed, 11 May 2005 The big guns of America’s mental health establishment — including the American Psychiatric and Psychological Associations and the National Alliance for the Mentally Ill — are making united front in support…
